ArticlePloS one2026
Health system costs and systemic treatment patterns by disease stage for 8577 people diagnosed with melanoma in New South Wales, Australia 2006-2019.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAustralia has the highest melanoma rates in the world. Melanoma is the third most common invasive cancer in Australia, and the number of in situ diagnoses is rapidly increasing. Treatment for non-localised stage melanoma is evolving, improving survival and increasing costs. We describe the costs and selected treatments by stage of disease for people diagnosed with melanoma in a large Australian cohort study.
methodsQuestionnaire data for participants in the Australian 45 and Up Study (n = 267,357 recruited 2005-2009) were linked with cancer registrations, hospital records and Medicare claims records. To estimate the government healthcare costs attributable to melanoma, total costs for each participant with melanoma were compared to costs for matched cancer-free controls. Multivariable gamma regression was used to estimate factors associated with costs. We also examined the distribution of melanoma treatments by disease stage.
resultsThere were 8577 participants diagnosed with melanoma after recruitment (5026 in situ and 3551 invasive; median age 69 years at diagnosis). The mean excess per-person costs in the first year after diagnosis ('initial phase') ranged from $2794 Australian dollars (US$1825) for in situ melanoma to $70,070 for distant metastases. The corresponding mean annual costs in the continuing care phase were $1222 and $38,470, respectively. Of 195 participants with regional/metastatic melanoma diagnosed 2014-2019, 80 (41%) had a record of immunotherapy/targeted therapy and their unadjusted per-person costs were approximately $60,000 higher annually than the 115 participants without these treatments.
conclusionsHealth system costs increased greatly with advancing melanoma stage, with higher costs linked to uptake of new immunotherapies/targeted therapies. Cost savings could arise from initiatives that detect and successfully treat melanomas at earlier stages, or prevent melanomas entirely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.